These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17036907)

  • 1. [Type 2 diabetes: hypoglycemia risk, weight gain... Will there soon be a new alternative to insulin?].
    MMW Fortschr Med; 2006 Sep; 148(37):54. PubMed ID: 17036907
    [No Abstract]   [Full Text] [Related]  

  • 2. [New data on hypoglycemia risk and beta cell function].
    MMW Fortschr Med; 2007 Nov; 149(44):57. PubMed ID: 18078171
    [No Abstract]   [Full Text] [Related]  

  • 3. Insulin therapy: friend, not foe. It's time to dispel common myths about insulin treatment for people with type 2 diabetes.
    Johns Hopkins Med Lett Health After 50; 2011 Jun; 23(4):4-5. PubMed ID: 21702113
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hypoglycemia--simply annoying or dangerous?].
    Kern W
    MMW Fortschr Med; 2016 Jun; 158(11):67-70. PubMed ID: 27271419
    [No Abstract]   [Full Text] [Related]  

  • 5. [Factors limiting glycaemic control in insulin-treated type 2 diabetes].
    Ferencz V; Domján B; Gerő L; Tänczer T; Tabák GÁ
    Orv Hetil; 2015 Sep; 156(36):1443-50. PubMed ID: 26320598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin therapy for type 2 diabetes.
    Swinnen SG; Hoekstra JB; DeVries JH
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S253-9. PubMed ID: 19875560
    [No Abstract]   [Full Text] [Related]  

  • 7. Dispelling myths and removing barriers about insulin in type 2 diabetes.
    Meece J
    Diabetes Educ; 2006; 32(1 Suppl):9S-18S. PubMed ID: 16439485
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements.
    Lane W; Weinrib S; Rappaport J
    Diabetes Technol Ther; 2011 May; 13(5):592-5. PubMed ID: 21406014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once weekly glucagon-like peptide-1 receptor agonist albiglutide vs. prandial insulin added to basal insulin in patients with type 2 diabetes mellitus: Results over 52 weeks.
    Leiter LA; Gross JL; Chow F; Miller D; Johnson S; Ahrén B;
    J Diabetes Complications; 2017 Aug; 31(8):1283-1285. PubMed ID: 28587789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early insulin use in type 2 diabetes: what are the cons?
    Chiasson JL
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S270-4. PubMed ID: 19875563
    [No Abstract]   [Full Text] [Related]  

  • 11. Starting insulin therapy in type 2 diabetes: lesson 1.
    McCall AL
    Curr Diab Rep; 2005 Oct; 5(5):325-6. PubMed ID: 16188164
    [No Abstract]   [Full Text] [Related]  

  • 12. [Insulin therapy in type 2 diabetes].
    Hummel M
    MMW Fortschr Med; 2011 Jun; 153(23):56-9, 61; quiz 62. PubMed ID: 21688497
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of insulin detemir in overweight type 2 diabetes management.
    Demssie YN; Younis N; Soran H
    Vasc Health Risk Manag; 2009; 5(3):553-60. PubMed ID: 19590589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.
    Schwartz SS; Jellinger PS; Herman ME
    Postgrad Med; 2016 Aug; 128(6):609-19. PubMed ID: 27210018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summaries for patients. Inhaled insulin with or instead of oral medications for type 2 diabetes.
    Ann Intern Med; 2005 Oct; 143(8):I28. PubMed ID: 16230717
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.
    Li CJ; Li J; Zhang QM; Lv L; Chen R; Lv CF; Yu P; Yu DM
    Cardiovasc Diabetol; 2012 Nov; 11():142. PubMed ID: 23153177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis.
    Chen C; Yu Q; Zhang S; Yang P; Wang CY
    Int J Clin Exp Pathol; 2015; 8(11):14141-50. PubMed ID: 26823727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
    Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
    Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose].
    MMW Fortschr Med; 2010 Oct; 152(40):44-5. PubMed ID: 21049644
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
    Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
    Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.